Abstract
We produced anti-ginsenoside Re (GRe)-4G10 monoclonal antibody that specifically recognizes GRe and used this to prepare an immunoaffinity column to remove GRe from American ginseng berry extract (AGBE) (thus producing GRe knock-out AGBE (GRe-KO-AGBE)). We compared the anti-diabetic and anti-obesity effects of AGBE and GRe- KO-AGBE in adult diabetic C57BL/6J ob/ob mice. Fasting blood glucose levels and body weight were measured in mice receiving daily intraperitoneal injections of 150 mg/kg of either extract for 27 consecutive days. On Day 6, the group taking AGBE had significantly lower fasting blood glucose levels compared to GRe-KO-AGBE-treated mice (70.5 mg/dl vs. 140 mg/dl). On Day 13, the glucose levels in both groups were 201 mg/dl for AGBE-treated group and 169 mg/dl for GRe-KO-AGBE, respectively. GRe (20 mg/kg) had dose-related effects on fasting blood glucose levels (reduced to 188 and 180 mg/dl on Day 5 and Day 12, respectively, compared to 229 and 235 mg/dl, respectively, in the vehicle group). This hypoglycemic effect persisted even after treatment discontinued (blood glucose levels at 3 days post-treatment: 198 and 253 mg/dl with ginsenoside and vehicle treatment, respectively). The monoclonal antibody technique can be used to prepare botanical knockout extracts for bioactivity studies.
Keywords: American ginseng berry, ginsenoside Re, knockout extract, monoclonal antibody
Current Drug Discovery Technologies
Title: Bioactivity of American Ginseng by Knockout Extract Preparation Using Monoclonal Antibody
Volume: 8 Issue: 1
Author(s): Chun-Su Yuan and Hiroyuki Tanaka
Affiliation:
Keywords: American ginseng berry, ginsenoside Re, knockout extract, monoclonal antibody
Abstract: We produced anti-ginsenoside Re (GRe)-4G10 monoclonal antibody that specifically recognizes GRe and used this to prepare an immunoaffinity column to remove GRe from American ginseng berry extract (AGBE) (thus producing GRe knock-out AGBE (GRe-KO-AGBE)). We compared the anti-diabetic and anti-obesity effects of AGBE and GRe- KO-AGBE in adult diabetic C57BL/6J ob/ob mice. Fasting blood glucose levels and body weight were measured in mice receiving daily intraperitoneal injections of 150 mg/kg of either extract for 27 consecutive days. On Day 6, the group taking AGBE had significantly lower fasting blood glucose levels compared to GRe-KO-AGBE-treated mice (70.5 mg/dl vs. 140 mg/dl). On Day 13, the glucose levels in both groups were 201 mg/dl for AGBE-treated group and 169 mg/dl for GRe-KO-AGBE, respectively. GRe (20 mg/kg) had dose-related effects on fasting blood glucose levels (reduced to 188 and 180 mg/dl on Day 5 and Day 12, respectively, compared to 229 and 235 mg/dl, respectively, in the vehicle group). This hypoglycemic effect persisted even after treatment discontinued (blood glucose levels at 3 days post-treatment: 198 and 253 mg/dl with ginsenoside and vehicle treatment, respectively). The monoclonal antibody technique can be used to prepare botanical knockout extracts for bioactivity studies.
Export Options
About this article
Cite this article as:
Yuan Chun-Su and Tanaka Hiroyuki, Bioactivity of American Ginseng by Knockout Extract Preparation Using Monoclonal Antibody, Current Drug Discovery Technologies 2011; 8 (1) . https://dx.doi.org/10.2174/157016311794519992
DOI https://dx.doi.org/10.2174/157016311794519992 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Corticosteroid as an Adjunct in the Treatment of Endobronchial Tuberculosis: A Systematic Review & Meta-analysis
Current Pediatric Reviews Sex Steroid Hormones, Cardiovascular Diseases and The Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Patients with Prehypertension - Do we have Enough Evidence to Treat them?
Current Vascular Pharmacology Heart Rate Variability Indexes in Dementia: A Systematic Review with a Quantitative Analysis
Current Alzheimer Research Editorial
Current Enzyme Inhibition Recent Patents on Ocular Drug Delivery Systems
Recent Patents on Drug Delivery & Formulation Modulation of Energy Intake and Expenditure Due to Habitual Physical Exercise
Current Pharmaceutical Design Mechanisms of Esophageal Protection, Gastroprotection and Ulcer Healing by Melatonin. Implications for the Therapeutic use of Melatonin in Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease
Current Pharmaceutical Design The Effect of Treatments for Rheumatoid Arthritis on Endothelial Dysfunction Evaluated by Flow-Mediated Vasodilation in Patients with Rheumatoid Arthritis
Current Vascular Pharmacology Metabolic Syndrome - Risk Factors for Atherosclerosis and Diabetes
Current Diabetes Reviews The Effects of Interleukin-10 on the Expression of Fas and FasL in Rat Hepatic Stellate Cells
Medicinal Chemistry GUT Microbiome-GUT Dysbiosis-Arterial Hypertension: New Horizons
Current Hypertension Reviews Potential Impact of MicroRNA-423 Gene Variability in Coronary Artery Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Is Later Obesity Programmed In Utero?
Current Drug Targets The Role of Renal Nerve Ablation for the Management of Resistant Hypertension and other Disease Conditions: Benefits and Concerns
Current Vascular Pharmacology Subject Index To Volume 12
Current Pharmaceutical Design Peptidergic Regulation of Pheochromocytoma
Current Pharmacogenomics Mitochondrion-Specific Antioxidants as Drug Treatments for Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Cellular Actions of Nesfatin-1 on Hypothalamic and Medullary Neurons
Current Pharmaceutical Design Assessment of Admission Time Cell Blood Count (CBC) Parameters in Predicting Post-primary Percutaneous Coronary Intervention TIMI Frame Count in Patients with ST-segment Elevation Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets